Potential of Cardiac Myosin Binding Protein-C as an Alternative Biomarker in Feline Hypertrophic Cardiomyopathy https://doi.org/10.12982/VIS.2026.029
Article Sidebar
Main Article Content
Abstract
Cardiac myosin binding protein-C (cMyBP-C) is a sarcomeric thick filament protein in cardiomyocytes. Its functions extend beyond cross-bridge regulation via dynamic phosphorylation to include sarcomere organization. Diminished cMyBP-C phosphorylation is associated with impaired cardiac function and the development of heart failure. Throughout the past decade, cMyBP-C has emerged as a new early cardiac biomarker for acute myocardial infarction (MI) due to its rapid release and clearance compared to cardiac troponin. In veterinary medicine, cMyBP-C remains a less understood biomarker. Recent studies suggest that genetic variations in cMyBP-C are related to hypertrophic cardiomyopathy (HCM) in cats, a common cardiac disorder defined by increased left ventricular (LV) thickness and diastolic dysfunction. Nevertheless, the role of circulating plasma cMyBP-C levels in feline HCM remains unestablished, representing a critical gap in veterinary cardiology research. Given the progressive nature of feline HCM and the lack of highly specific early biomarkers, plasma cMyBP-C could serve as a valuable tool for early detection and disease monitoring. This review presents a comprehensive analysis of the physiological and pathological roles of cMyBP-C in cardiac function, its association with cardiovascular diseases, the dynamics of its circulating levels, and the factors regulating its release. These insights highlight the potential of cMyBP-C as a promising early biomarker for diagnosing and monitoring feline hypertrophic cardiomyopathy.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publishing an article with open access in Veterinary Integrative Sciences leaves the copyright with the author. The article is published under the Creative Commons Attribution License 4.0 (CC-BY 4.0), which allows users to read, copy, distribute and make derivative works from the material, as long as the author of the original work is cited.
References
Alaour, B., Kaier, T., Demir, Z., Van Doorn, W., Kimenai, D., Zar, A., Van Der Linden, N., Marber, M., Meex, S.J.E.H.J., 2021. Physiological circadian rhythm of cardiac myosin-binding protein C (cMyC) and cardiac troponin. Eur. Heart. J. 42, ehab724.1395.
Alaour, B., Omland, T., Torsvik, J., Kaier, T.E., Sylte, M.S., Strand, H., Quraishi, J., McGrath, S., Williams, L., Meex, S., Redwood, S., Marber, M., Aakre, K.M., 2022. Biological variation of cardiac myosin-binding protein C in healthy individuals. Clin. Chem. Lab. Med. 60(4), 576-583.
Anand, A., Chin, C., Shah, A.S.V., Kwiecinski, J., Vesey, A., Cowell, J., Weber, E., Kaier, T., Newby, D.E., Dweck, M., Marber, M.S., Mills, N.L., 2018. Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis. Heart. 104(13), 1101-1108.
Baker, J.O., Tyther, R., Liebetrau, C., Clark, J., Howarth, R., Patterson, T., Mollmann, H., Nef, H., Sicard, P., Kailey, B., Devaraj, R., Redwood, S.R., Kunst, G., Weber, E., Marber, M.S., 2015. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res. Cardiol. 110(3), 23.
Barefield, D., Sadayappan, S., 2010. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J. Mol. Cell. Cardiol. 48(5), 866-875.
Betocchi, S., Hess, O.M., Losi, M.A., Nonogi, H., Krayenbuehl, H.P., 1993. Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation. 88, 2206-2214.
Bezold, K.L., Shaffer, J.F., Khosa, J.K., Hoye, E.R., Harris, S.P., 2013. A gain-of-function mutation in the M-domain of cardiac myosin-binding protein-C increases binding to actin. J. Biol. Chem. 288(30), 21496-21505.
Booth, J., Pinney, J., Davenport, A., 2010. N-terminal proBNP--marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clin. J. Am. Soc. Nephrol. 5(6), 1036-1040.
Borgeat, K., Sherwood, K., Payne, J.R., Luis Fuentes, V., Connolly, D.J., 2014. Plasma cardiac troponin I concentration and cardiac death in cats with hypertrophic cardiomyopathy. J. Vet. Intern. Med. 28(6), 1731-1737.
Carlos Sampedrano, C., Chetboul, V., Mary, J., Tissier, R., Abitbol, M., Serres, F., Gouni, V., Thomas, A., Pouchelon, J.L., 2009. Prospective echocardiographic and tissue Doppler imaging screening of a population of Maine Coon cats tested for the A31P mutation in the myosin-binding protein C gene: a specific analysis of the heterozygous status. J. Vet. Intern. Med. 23(1), 91-99.
Carrier, L., Mearini, G., Stathopoulou, K., Cuello, F., 2015. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. 573(2), 188-197.
Cesta, M.F., Baty, C.J., Keene, B.W., Smoak, I.W., Malarkey, D.E., 2005. Pathology of end-stage remodeling in a family of cats with hypertrophic cardiomyopathy. Vet. Pathol. 42(4), 458-467.
Charkiewicz, A.E., Garley, M., Ratajczak-Wrona, W., Jablonska, E., Miltyk, W., Motyka, J., Omeljaniuk, W.J., 2022. The diagnostic potential of novel biomarkers of hypertension in men. Arch. Med. Sci. 18(6), 1666-1671.
Charron, P., Dubourg, O., Desnos, M., Bennaceur, M., Carrier, L., Camproux, A.C., Isnard, R., Hagege, A., Langlard, J.M., Bonne, G., Richard, P., Hainque, B., Bouhour, J.B., Schwartz, K., Komajda, M., 1998. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 97(22), 2230-2236.
Chien, Y., Chien, C.S., Chiang, H.C., Huang, W.L., Chou, S.J., Chang, W.C., Chang, Y.L., Leu, H.B., Chen, K.H., Wang, K.L., Lai, Y.H., Liu, Y.Y., Lu, K.H., Li, H.Y., Sung, Y.J., Jong, Y.J., Chen, Y.J., Chen, C.H., Yu, W.C., 2016. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget. 7(52), 87161-87179.
Chong, A., Joshua, J., Raheb, S., Pires, A., Colpitts, M., Caswell, J.L., Fonfara, S., 2024. Evaluation of potential novel biomarkers for feline hypertrophic cardiomyopathy. Res. Vet. Sci. 180, 105430.
Connolly, D.J., Cannata, J., Boswood, A., Archer, J., Groves, E.A., Neiger, R., 2003. Cardiac troponin I in cats with hypertrophic cardiomyopathy. J. Feline Med. Surg. 5(4), 209-216.
Connolly, D.J., Soares Magalhaes, R.J., Fuentes, V.L., Boswood, A., Cole, G., Boag, A., Syme, H.M., 2009. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J. Vet. Cardiol. 11, S41-50.
Decker, R.S., Decker, M.L., Kulikovskaya, I., Nakamura, S., Lee, D.C., Harris, K., Klocke, F.J., Winegrad, S., 2005. Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation. 111(7), 906-912.
Decker, R.S., Nakamura, S., Decker, M.L., Sausamuta, M., Sinno, S., Harris, K., Klocke, F.J., Kulikovskaya, I., Winegrad, S., 2012. The dynamic role of cardiac myosin binding protein-C during ischemia. J. Mol. Cell. Cardiol. 52(5), 1145-1154.
Doh, C.Y., Li, J., Mamidi, R., Stelzer, J.E., 2019. The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure. Biochim. Biophys. Acta. Mol. Basis. Dis. 1865(3), 661-677.
Eggers, K.M., Jernberg, T., Lindahl, B., 2019. Cardiac Troponin elevation in patients without a specific diagnosis. J. Am. Coll. Cardiol. 73(1), 1-9.
Ehler, E., Rothen, B.M., Hammerle, S.P., Komiyama, M., Perriard, J.C., 1999. Myofibrillogenesis in the developing chicken heart: assembly of Z-disk, M-line and the thick filaments. J. Cell Sci. 112, 1529-1539.
El-Armouche, A., Pohlmann, L., Schlossarek, S., Starbatty, J., Yeh, Y.H., Nattel, S., Dobrev, D., Eschenhagen, T., Carrier, L., 2007. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J. Mol. Cell. Cardiol. 43(2), 223-229.
El-Moghazy, E.M., Morsy, S.M., Abdallah, S.H., Ali, M.A., 2020. Cardiac myosin binding protein C plasma level as a diagnostic and prognostic biomarker in heart failure in children. 80(3), 1097-1102.
El Amrousy, D., Hodeib, H., Suliman, G., Hablas, N., Salama, E.R., Esam, A., 2017. Diagnostic and prognostic value of plasma levels of cardiac myosin binding protein-c as a novel biomarker in heart failure. Pediatr. Cardiol. 38(2), 418-424.
Ferasin, L., DeFrancesco, T., 2015. Management of acute heart failure in cats. J. Vet. Cardiol. 17 Suppl 1, S173-189.
Flashman, E., Redwood, C., Moolman-Smook, J., Watkins, H., 2004. Cardiac myosin binding protein C: its role in physiology and disease. Circ. Res. 94(10), 1279-1289.
Fonfara, S., Kitz, S., Monteith, G., Hahn, S., Kipar, A., 2021. Myocardial transcription of inflammatory and remodeling markers in cats with hypertrophic cardiomyopathy and systemic diseases associated with an inflammatory phenotype. Res. Vet. Sci. 136, 484-494.
Fox, P.R., Oyama, M.A., Reynolds, C., Rush, J.E., DeFrancesco, T.C., Keene, B.W., Atkins, C.E., Macdonald, K.A., Schober, K.E., Bonagura, J.D., Stepien, R.L., Kellihan, H.B., Nguyenba, T.P., Lehmkuhl, L.B., Lefbom, B.K., Moise, N.S., Hogan, D.F., 2009. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J. Vet. Cardiol. 11, S51-61.
Freeman, L.M., Rush, J.E., Stern, J.A., Huggins, G.S., Maron, M.S., 2017. Feline hypertrophic cardiomyopathy: a spontaneous large animal model of human HCM. Cardiol. Res. 8(4), 139-142.
Gautel, M., Zuffardi, O., Freiburg, A., Labeit, S., 1995. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 14(9), 1952-1960.
Gawor, M., Spiewak, M., Janas, J., Kozuch, K., Wrobel, A., Mazurkiewicz, L., Baranowski, R., Marczak, M., Grzybowski, J., 2017. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol. Pol. 75(10), 997-1004.
Godiksen, M.T., Granstrom, S., Koch, J., Christiansen, M., 2011. Hypertrophic cardiomyopathy in young Maine Coon cats caused by the p.A31P cMyBP-C mutation--the clinical significance of having the mutation. Acta Vet. Scand. 53, 7.
Govindan, S., Kuster, D.W., Lin, B., Kahn, D.J., Jeske, W.P., Walenga, J.M., Leya, F., Hoppensteadt, D., Fareed, J., Sadayappan, S., 2013. Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Am. J. Cardiovasc. Dis. 3(2), 60-70.
Govindan, S., McElligott, A., Muthusamy, S., Nair, N., Barefield, D., Martin, J.L., Gongora, E., Greis, K.D., Luther, P.K., Winegrad, S., Henderson, K.K., Sadayappan, S., 2012. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J. Mol. Cell. Cardiol. 52(1), 154-164.
Gruen, M., Prinz, H., Gautel, M., 1999. cAPK-phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin-S2 in an on-off fashion. FEBS Lett. 453(3), 254-259.
Hanas, S., Holst, B.S., Hoglund, K., Haggstrom, J., Tidholm, A., Ljungvall, I., 2020. Effect of feline characteristics on plasma N-terminal-prohormone B-type natriuretic peptide concentration and comparison of a point-of-care test and an ELISA test. J. Vet. Intern. Med. 34(3), 1187-1197.
Hanas, S., Larsson, A., Ryden, J., Lilliehook, I., Haggstrom, J., Tidholm, A., Hoglund, K., Ljungvall, I., Holst, B.S., 2022. Cardiac troponin I in healthy Norwegian Forest Cat, Birman and domestic shorthair cats, and in cats with hypertrophic cardiomyopathy. J. Feline Med. Surg. 24(10), e370-e379.
Hara, A., Niwa, M., Kanayama, T., Noguchi, K., Niwa, A., Matsuo, M., Kuroda, T., Hatano, Y., Okada, H., Tomita, H., 2020. Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules. 10(9), 1277.
Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., Tomita, H., 2020. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules. 10(3), 389.
Hartzell, H.C., Glass, D.B., 1984. Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca2+-calmodulin-dependent protein kinases. J. Biol. Chem. 259(24), 15587-15596.
Hassdenteufel, E., Henrich, E., Hildebrandt, N., Stosic, A., Schneider, M., 2013. Assessment of circulating N-terminal pro B-type natriuretic peptide concentration to differentiate between cardiac from noncardiac causes of pleural effusion in cats. J. Vet. Emerg. Crit. Care (San Antonio). 23(4), 416-422.
Heald, A.H., Kaushal, K., Siddals, K.W., Rudenski, A.S., Anderson, S.G., Gibson, J.M., 2006. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes. 114(7), 371-376.
Heather, L.C., Howell, N.J., Emmanuel, Y., Cole, M.A., Frenneaux, M.P., Pagano, D., Clarke, K., 2011. Changes in cardiac substrate transporters and metabolic proteins mirror the metabolic shift in patients with aortic stenosis. PLoS One. 6(10), e26326.
Helms, A.S., Thompson, A.D., Glazier, A.A., Hafeez, N., Kabani, S., Rodriguez, J., Yob, J.M., Woolcock, H., Mazzarotto, F., Lakdawala, N.K., Wittekind, S.G., Pereira, A.C., Jacoby, D.L., Colan, S.D., Ashley, E.A., Saberi, S., Ware, J.S., Ingles, J., Semsarian, C., Michels, M., Olivotto, I., Ho, C.Y., Day, S.M., 2020. Spatial and functional distribution of MYBPC3 pathogenic variants and clinical outcomes in patients with hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. 13(5), 396-405.
Herndon, W.E., Rishniw, M., Schrope, D., Sammarco, C.D., Boddy, K.N., Sleeper, M.M., 2008. Assessment of plasma cardiac troponin I concentration as a means to differentiate cardiac and noncardiac causes of dyspnea in cats. J. Am. Vet. Med. Assoc. 233(8), 1261-1264.
Ho, C.Y., 2012. Genetic considerations in hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 54(6), 456-460.
Hori, Y., Iguchi, M., Heishima, Y., Yamashita, Y., Nakamura, K., Hirakawa, A., Kitade, A., Ibaragi, T., Katagi, M., Sawada, T., Yuki, M., Kanno, N., Inaba, H., Isayama, N., Onodera, H., Iwasa, N., Kino, M., Narukawa, M., Uchida, S., 2018. Diagnostic utility of cardiac troponin I in cats with hypertrophic cardiomyopathy. J. Vet. Intern. Med. 32(3), 922-929.
Jacques, A.M., Copeland, O., Messer, A.E., Gallon, C.E., King, K., McKenna, W.J., Tsang, V.T., Marston, S.B., 2008. Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. J. Mol. Cell. Cardiol. 45(2), 209-216.
Jacquet, S., Yin, X., Sicard, P., Clark, J., Kanaganayagam, G.S., Mayr, M., Marber, M.S., 2009. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol. Cell. Proteomics. 8(12), 2687-2699.
Jiang, L., Liu, S., Deng, T., Yang, Y., Zhang, Y., 2022. Analysis of the expression, function and signaling of glycogen phosphorylase isoforms in hepatocellular carcinoma. Oncol. Lett. 24(2), 244.
Kaier, T.E., Stengaard, C., Marjot, J., Sorensen, J.T., Alaour, B., Stavropoulou-Tatla, S., Terkelsen, C.J., Williams, L., Thygesen, K., Weber, E., Marber, M., Botker, H.E., 2019. Cardiac myosin-binding protein C to diagnose acute myocardial infarction in the pre-hospital setting. J. Am. Heart. Assoc. 8(15), e013152.
Kaier, T.E., Twerenbold, R., Puelacher, C., Marjot, J., Imambaccus, N., Boeddinghaus, J., Nestelberger, T., Badertscher, P., Sabti, Z., Gimenez, M.R., Wildi, K., Hillinger, P., Grimm, K., Loeffel, S., Shrestha, S., Widmer, D.F., Cupa, J., Kozhuharov, N., Miro, O., Martin-Sanchez, F.J., Morawiec, B., Rentsch, K., Lohrmann, J., Kloos, W., Osswald, S., Reichlin, T., Weber, E., Marber, M., Mueller, C., 2017. Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction. Circulation. 136(16), 1495-1508.
Katrukha, I.A., Katrukha, A.G., 2021. Myocardial injury and the release of troponins I and T in the blood of patients. Clin. Chem. 67(1), 124-130.
Khatab, A.A., El-Gazzar, B.A., Rizk, M.S., Ghani, M.G.F.A., 2021. Value of plasma levels of cardiac myosin-binding protein C as a diagnostic and prognostic biomarker in heart failure. Menoufia Med. J. 34(1), 221.
Kittleson, M.D., Cote, E., 2021. The feline cardiomyopathies: 2. hypertrophic cardiomyopathy. J. Feline. Med. Surg. 23(11), 1028-1051.
Kitz, S., Fonfara, S., Hahn, S., Hetzel, U., Kipar, A., 2019. Feline hypertrophic cardiomyopathy: the consequence of cardiomyocyte-initiated and macrophage-driven remodeling processes? Vet. Pathol. 56(4), 565-575.
Konishi, K., Sakamoto, M., Satake, C., Isaka, M., Okazaki, S., Kono, S., Nakamura, T., Tashiro, H., Ushigusa, T., 2022. Perioperative changes in cardiac biomarkers in juvenile cats during neutering. Front. Vet. Sci. 9, 1008765.
Kozhuharov, N., Wussler, D., Kaier, T., Strebel, I., Shrestha, S., Flores, D., Nowak, A., Sabti, Z., Nestelberger, T., Zimmermann, T., Walter, J., Belkin, M., Michou, E., Lopez Ayala, P., Gualandro, D.M., Keller, D.I., Goudev, A., Breidthardt, T., Mueller, C., Marber, M., Investigators, B.V., 2021. Cardiac myosin-binding protein C in the diagnosis and risk stratification of acute heart failure. Eur. J. Heart Fail. 23(5), 716-725.
Kulikovskaya, I., McClellan, G., Flavigny, J., Carrier, L., Winegrad, S., 2003. Effect of MyBP-C binding to actin on contractility in heart muscle. J. Gen. Physiol. 122(6), 761-774.
Kuster, D.W., Cardenas-Ospina, A., Miller, L., Liebetrau, C., Troidl, C., Nef, H.M., Mollmann, H., Hamm, C.W., Pieper, K.S., Mahaffey, K.W., Kleiman, N.S., Stuyvers, B.D., Marian, A.J., Sadayappan, S., 2014. Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 306(4), H547-556.
Lalor, S.M., Connolly, D.J., Elliott, J., Syme, H.M., 2009. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J. Vet. Cardiol. 11 Suppl 1, S71-79.
Langhorn, R., Tarnow, I., Willesen, J.L., Kjelgaard-Hansen, M., Skovgaard, I.M., Koch, J., 2014. Cardiac troponin I and T as prognostic markers in cats with hypertrophic cardiomyopathy. J. Vet. Intern. Med. 28(5), 1485-1491.
Langhorn, R., Willesen, J.L., Tarnow, I., Kjelgaard-Hansen, M., 2013. Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I. Vet. Clin. Pathol. 42(4), 490-498.
Levine, R., Weisberg, A., Kulikovskaya, I., McClellan, G., Winegrad, S., 2001. Multiple structures of thick filaments in resting cardiac muscle and their influence on cross-bridge interactions. Biophys. J. 81(2), 1070-1082.
Lim, M.S., Sutherland, C., Walsh, M.P., 1985. Phosphorylation of bovine cardiac C-protein by protein kinase C. Biochem. Biophys. Res. Commun. 132(3), 1187-1195.
Lin, B.L., Li, A., Mun, J.Y., Previs, M.J., Previs, S.B., Campbell, S.G., Dos Remedios, C.G., Tombe, P.P., Craig, R., Warshaw, D.M., Sadayappan, S., 2018. Skeletal myosin binding protein-C isoforms regulate thin filament activity in a Ca(2+)-dependent manner. Sci. Rep. 8(1), 2604.
Lindner, G., Pfortmueller, C.A., Braun, C.T., Exadaktylos, A.K., 2014. Non-acute myocardial infarction-related causes of elevated high-sensitive troponin T in the emergency room: a cross-sectional analysis. Intern. Emerg. Med. 9(3), 335-339.
Longeri, M., Ferrari, P., Knafelz, P., Mezzelani, A., Marabotti, A., Milanesi, L., Pertica, G., Polli, M., Brambilla, P.G., Kittleson, M., Lyons, L.A., Porciello, F., 2013. Myosin-binding protein C DNA variants in domestic cats (A31P, A74T, R820W) and their association with hypertrophic cardiomyopathy. J. Vet. Intern. Med. 27(2), 275-285.
Lopez, B., Gonzalez, A., Querejeta, R., Zubillaga, E., Larman, M., Diez, J., 2015. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur. J. Heart Fail. 17(4), 385-392.
Lu, T.L., Cote, E., Kuo, Y.W., Wu, H.H., Wang, W.Y., Hung, Y.W., 2021. Point-of-care N-terminal pro B-type natriuretic peptide assay to screen apparently healthy cats for cardiac disease in general practice. J. Vet. Intern. Med. 35(4), 1663-1672.
Luis Fuentes, V., Abbott, J., Chetboul, V., Cote, E., Fox, P.R., Haggstrom, J., Kittleson, M.D., Schober, K., Stern, J.A., 2020. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J. Vet. Intern. Med. 34(3), 1062-1077.
Main, A., Fuller, W., Baillie, G.S., 2020. Post-translational regulation of cardiac myosin binding protein-C: a graphical review. Cell. Signal. 76, 109788.
Mainville, C.A., Clark, G.H., Esty, K.J., Foster, W.M., Hanscom, J.L., Hebert, K.J., Lyons, H.R., 2015. Analytical validation of an immunoassay for the quantification of N-terminal pro-B-type natriuretic peptide in feline blood. J. Vet. Diagn. Invest. 27(4), 414-421.
Marín-García, J.J.E.A., 2014. Cardiomyopathies: a comparative analysis of phenotypes and genotypes. pp. 363-426.
McClellan, G., Kulikovskaya, I., Winegrad, S., 2001. Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys. J. 81(2), 1083-1092.
McClellan, G., Weisberg, A., Winegrad, S., 1994. cAMP can raise or lower cardiac actomyosin ATPase activity depending on alpha-adrenergic activity. Am. J. Physiol. 267, H431-442.
Migita, T., Narita, T., Asaka, R., Miyagi, E., Nagano, H., Nomura, K., Matsuura, M., Satoh, Y., Okumura, S., Nakagawa, K., Seimiya, H., Ishikawa, Y., 2010. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am. J. Pathol. 176(4), 1756-1766.
Mohamed, A.S., Dignam, J.D., Schlender, K.K., 1998. Cardiac myosin-binding protein C (MyBP-C): identification of protein kinase A and protein kinase C phosphorylation sites. Arch. Biochem. Biophys. 358(2), 313-319.
Nabeel, D., Zhang, J., Lu, X., 2017. MyBP-C in cardiac conditions and its potential use as novel biomarker: a review. Eur. Acad. Res. 5, 1352-1368.
Offer, G., Moos, C., Starr, R., 1973. A new protein of the thick filaments of vertebrate skeletal myofibrils. Extractions, purification and characterization. J. Mol. Biol. 74(4), 653-676.
Olalekan, S.O., Bakare, O.O., Okwute, P.G., Osonuga, I.O., Adeyanju, M.M., Edema, V.B., 2025. Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies. Egypt Heart J. 77, 5.
Pace, C., 2020. A practical guide to the new feline cardiomyopathy consensus statement. Vet. Nurs. 11(8), 375-378.
Parbhudayal, R.Y., Garra, A.R., Gotte, M.J.W., Michels, M., Pei, J., Harakalova, M., Asselbergs, F.W., van Rossum, A.C., van der Velden, J., Kuster, D.W.D., 2018. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 123, 59-63.
Park, K.C., Gaze, D.C., Collinson, P.O., Marber, M.S., 2017. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc. Res. 113(14), 1708-1718.
Payne, J.R., Brodbelt, D.C., Luis Fuentes, V., 2015. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). J. Vet. Cardiol. 17, S244-257.
Pierce, K.V., Rush, J.E., Freeman, L.M., Cunningham, S.M., Yang, V.K., 2017. Association between survival time and changes in NT-proBNP in cats treated for congestive heart failure. J. Vet. Intern. Med. 31(3), 678-684.
Potter, J.M., Hickman, P.E., Cullen, L., 2022. Troponins in myocardial infarction and injury. Aust. Prescr. 45(2), 53-57.
Pyle, W.G., Chen, Y., Hofmann, P.A., 2003. Cardioprotection through a PKC-dependent decrease in myofilament ATPase. Am. J. Physiol. Heart Circ. Physiol. 285(3), H1220-1228.
Ren, L.K., Lu, R.S., Fei, X.B., Chen, S.J., Liu, P., Zhu, C.H., Wang, X., Pan, Y.Z., 2024. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target. J. Cancer Res. Clin. Oncol. 150(3), 127.
Riesen, S.C., Kovacevic, A., Lombard, C.W., Amberger, C., 2007. Prevalence of heart disease in symptomatic cats: an overview from 1998 to 2005. Schweiz. Arch. Tierheilkd. 149(2), 65-71.
Sadayappan, S., de Tombe, P.P., 2012. Cardiac myosin binding protein-C: redefining its structure and function. Biophys. Rev. 4(2), 93-106.
Sadayappan, S., Gulick, J., Osinska, H., Martin, L.A., Hahn, H.S., Dorn, G.W., Klevitsky, R., Seidman, C.E., Seidman, J.G., Robbins, J., 2005. Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ. Res. 97(11), 1156-1163.
Schlender, K.K., Bean, L.J., 1991. Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. J. Biol. Chem. 266(5), 2811-2817.
Schlossarek, S., Mearini, G., Carrier, L., 2011. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J. Mol. Cell. Cardiol. 50(4), 613-620.
Shaffer, J.F., Kensler, R.W., Harris, S.P., 2009. The myosin-binding protein C motif binds to F-actin in a phosphorylation-sensitive manner. J. Biol. Chem. 284(18), 12318-12327.
Singh, M.K., Cocchiaro, M.F., Kittleson, M.D., 2010. NT-proBNP measurement fails to reliably identify subclinical hypertrophic cardiomyopathy in Maine Coon cats. J. Feline Med. Surg. 12(12), 942-947.
Stack, J.P., Fries, R.C., Kruckman, L., Kadotani, S., Wallace, G., 2023. Galectin-3 as a novel biomarker in cats with hypertrophic cardiomyopathy. J. Vet. Cardiol. 48, 54-62.
Stelzer, J.E., Patel, J.R., Moss, R.L., 2006. Protein kinase A-mediated acceleration of the stretch activation response in murine skinned myocardium is eliminated by ablation of cMyBP-C. Circ. Res. 99(8), 884-890.
Stelzer, J.E., Patel, J.R., Walker, J.W., Moss, R.L., 2007. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myofibrillar force responses to protein kinase A phosphorylation. Circ. Res. 101(5), 503-511.
Stenson, P.D., Mort, M., Ball, E.V., Shaw, K., Phillips, A., Cooper, D.N., 2014. The human gene mutation database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 133(1), 1-9.
Stern, J.A., Rivas, V.N., Kaplan, J.L., Ueda, Y., Oldach, M.S., Ontiveros, E.S., Kooiker, K.B., van Dijk, S.J., Harris, S.P., 2023. Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C. Sci. Rep. 13(1), 10319.
Sukumolanan, P., Petchdee, S., 2020. Feline hypertrophic cardiomyopathy: genetics, current diagnosis and management. Vet. Integr. Sci. 18(2), 61-73.
Sun, Y.L., Dookhun, M.N., Lu, X.Z., 2019. Correlation between myocardial myosin-binding protein C, hypertension with left ventricular enlargement, and dilated cardiomyopathy. Cardiol. Plus. 4(4), 111-115.
Tanindi, A., Cemri, M., 2011. Troponin elevation in conditions other than acute coronary syndromes. Vasc. Health. Risk. Manag. 7, 597-603.
Tanjore, R.R., Rangaraju, A., Kerkar, P.G., Calambur, N., Nallari, P., 2008. MYBPC3 gene variations in hypertrophic cardiomyopathy patients in India. Can. J. Cardiol. 24(2), 127-130.
Tantisuwat, L., Puangampai, P., Panpakdee, P., Tangarsasilp, T., Surachetpong, S.D., 2018. Survival time and prognosis factors in hypertrophic cardiomyopathy cats with congestive heart failure. Thai J. Vet. Med. 48(4), 655-662.
Tong, C.W., Stelzer, J.E., Greaser, M.L., Powers, P.A., Moss, R.L., 2008. Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ. Res. 103(9), 974-982.
van Dijk, S.J., Dooijes, D., dos Remedios, C., Michels, M., Lamers, J.M., Winegrad, S., Schlossarek, S., Carrier, L., ten Cate, F.J., Stienen, G.J., van der Velden, J., 2009. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 119(11), 1473-1483.
Waldmuller, S., Erdmann, J., Binner, P., Gelbrich, G., Pankuweit, S., Geier, C., Timmermann, B., Haremza, J., Perrot, A., Scheer, S., Wachter, R., Schulze-Waltrup, N., Dermintzoglou, A., Schonberger, J., Zeh, W., Jurmann, B., Brodherr, T., Borgel, J., Farr, M., Milting, H., Blankenfeldt, W., Reinhardt, R., Ozcelik, C., Osterziel, K.J., Loeffler, M., Maisch, B., Regitz-Zagrosek, V., Schunkert, H., Scheffold, T., German Competence Network Heart Failure, 2011. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. Eur. J. Heart Fail. 13(11), 1185-1192.
Walker, L.A., Fullerton, D.A., Buttrick, P.M., 2013. Contractile protein phosphorylation predicts human heart disease phenotypes. Am. J. Physiol. Heart Circ. Physiol. 304(12), H1644-1650.
Ward, J.L., Lisciandro, G.R., Ware, W.A., Viall, A.K., Aona, B.D., Kurtz, K.A., Reina-Doreste, Y., DeFrancesco, T.C., 2018. Evaluation of point-of-care thoracic ultrasound and NT-proBNP for the diagnosis of congestive heart failure in cats with respiratory distress. J. Vet. Intern. Med. 32(5), 1530-1540.
Weisberg, A., Winegrad, S., 1996. Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc. Natl. Acad. Sci. U. S. A. 93(17), 8999-9003.
Weisberg, A., Winegrad, S., 1998. Relation between crossbridge structure and actomyosin ATPase activity in rat heart. Circ. Res. 83(1), 60-72.
Wells, S.M., Shofer, F.S., Walters, P.C., Stamoulis, M.E., Cole, S.G., Sleeper, M.M., 2014. Evaluation of blood cardiac troponin I concentrations obtained with a cage-side analyzer to differentiate cats with cardiac and noncardiac causes of dyspnea. J. Am. Vet. Med. Assoc. 244(4), 425-430.
Xiao, L., Zhao, Q., Du, Y., Yuan, C., Solaro, R.J., Buttrick, P.M., 2007. PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo. Biochemistry. 46(23), 7054-7061.
Yang, C., Wang, H., Shao, M., Chu, F., He, Y., Chen, X., Fan, J., Chen, J., Cai, Q., Wu, C., 2024. Brain-Type Glycogen Phosphorylase (PYGB) in the pathologies of diseases: a systematic review. Cells. 13(3), 289.
Yang, J., Griffiths, M., Nies, M.K., Brandal, S., Damico, R., Vaidya, D., Tao, X., Simpson, C.E., Kolb, T.M., Mathai, S.C., Pauciulo, M.W., Nichols, W.C., Ivy, D.D., Austin, E.D., Hassoun, P.M., Everett, A.D., 2020. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Med. 18(1), 268.
